Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 16/20 | 0.51 |
| ▸ | EGFR | P00533 | 11/20 | 0.51 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.51 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | FECH | P22830 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.48 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3510630 | 0.88 | ERBB2 (0.46) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL5528620 | 0.77 | ERBB2 (0.60) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL3508232 | 0.72 | EGFR (0.58) | ERBB2EGFRERBB3ERBB4HDAC1 | |
| SCHEMBL1105274 | 0.71 | ERBB2 (0.56) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL5002315 | 0.71 | ERBB2 (0.56) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL2751517 | 0.69 | ERBB2 (0.64) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL2750670 | 0.69 | ERBB2 (0.52) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL2749960 | 0.69 | ERBB2 (0.63) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL2749945 | 0.69 | ERBB2 (0.63) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL2747892 | 0.68 | ERBB2 (0.65) | ERBB2EGFRERBB3ERBB4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-1987037-A2 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007097470-A2 | FUSED NITROGEN- COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | NR0B2, NR0B1, NR4A3 | ERBB2 195/4885EGFR 573/4885ERBB3 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.